"Declarations from generic drug makers alleged only possible future injury from implementation of the 2019 law that created a presumption that so-called “pay for delay” settlement agreements are anticompetitive." http://patentblog.kluweriplaw.com/2020/08/30/patent-case-association-for-accessible-medicines-v-becerra-usa/